[BCM] [ALPS] [E3] [BIA] [P3] [CBF] [2] Pharmaceutical Procurement and Supply Management

Written by Dr Goh Moh Heng | Aug 5, 2026, 10:08:56 AM

CBF-2 Pharmaceutical Procurement and Supply Management

An important objective of the Business Impact Analysis (BIA) is to understand not only the consequences of a business disruption, but also how those consequences escalate over time.

A short interruption to a pharmaceutical procurement activity may have minimal operational impact if alternative workarounds are available.

However, as the disruption continues, inventories decline, supplier commitments are missed, regulatory obligations accumulate, and the ability to maintain the continuous supply of medicines to healthcare institutions becomes increasingly compromised.

Analysing impact over time enables ALPS Healthcare to determine which Sub-Critical Business Functions require the earliest recovery and which activities can tolerate a longer interruption.

This progressive assessment reflects the cumulative effects of operational delays, contractual obligations, regulatory compliance requirements, supplier dependencies, patient safety considerations, and healthcare service continuity. The resulting prioritisation supports evidence-based decision-making during disruptive events.

The analysis also provides the basis for establishing the Recovery Time Objective (RTO), representing the target time by which a business function should be restored before unacceptable consequences occur, and the Maximum Tolerable Period of Disruption (MTPD), beyond which the organisation's ability to deliver Pharmaceutical Procurement and Supply Management is seriously threatened.

In addition, identifying Vulnerable Periods highlights operational windows—such as infectious disease outbreaks, medicine shortage events, contract renewals, or large-scale procurement exercises—during which disruptions would have a disproportionately severe impact. Together, these outputs guide continuity strategy development, resource allocation, and Business Continuity Planning.

Table P3: Impact Over Time of Business Functions for CBF-2

Sub-CBF Code	Sub-Critical Business Function	Highest-Impact Area	4 Hrs	8 Hrs	1 Day	2 Days	3 Days	5 Days	7 Days	10 Days	14 Days	21 Days	30 Days	60 Days	RTO	MTPD	Vulnerable Period
CBF-2.1	Pharmaceutical Demand Forecasting	Operational	1	2	2	3	3	4	4	5	5	5	5	5	24 Hours	5 Days	Disease outbreaks, seasonal demand surges, pandemic preparedness planning
CBF-2.2	Pharmaceutical Requirements Planning	Operational	1	2	3	3	4	4	5	5	5	5	5	5	24 Hours	5 Days	Monthly replenishment planning cycles and emergency demand increases
CBF-2.3	Approved Drug Catalogue Management	Regulatory	1	1	2	2	3	3	4	4	5	5	5	5	2 Days	10 Days	Introduction of new medicines and urgent formulary changes
CBF-2.4	Supplier Qualification and Evaluation	Third-Party Dependency	1	1	2	2	3	3	4	4	4	5	5	5	3 Days	14 Days	Qualification of new suppliers during supply shortages
CBF-2.5	Pharmaceutical Tender and Sourcing Management	Operational	1	2	3	4	4	5	5	5	5	5	5	5	2 Days	7 Days	National procurement exercises and expiring framework agreements
CBF-2.6	Contract and Pricing Management	Financial	1	1	2	3	3	4	4	4	5	5	5	5	3 Days	14 Days	Contract renewals and emergency price negotiations
CBF-2.7	Purchase Order Processing	Operational	2	3	4	4	5	5	5	5	5	5	5	5	8 Hours	3 Days	Daily procurement processing for essential medicines
CBF-2.8	Regulatory and Product Compliance Verification	Regulatory	2	3	4	4	5	5	5	5	5	5	5	5	8 Hours	3 Days	Procurement of regulated pharmaceuticals and emergency imports
CBF-2.9	Pharmaceutical Supply Scheduling	Third-Party Dependency	2	2	3	4	4	5	5	5	5	5	5	5	1 Day	5 Days	Major shipment arrivals and nationwide replenishment schedules
CBF-2.10	Pharmaceutical Receipt and Inspection Coordination	Operational	2	2	3	4	4	5	5	5	5	5	5	5	1 Day	5 Days	High-volume medicine deliveries and emergency shipments
CBF-2.11	Cold Chain and Controlled Storage Coordination	Operational	3	4	5	5	5	5	5	5	5	5	5	5	4 Hours	24 Hours	Vaccine campaigns, biologic deliveries, temperature-sensitive medicines
CBF-2.12	Pharmaceutical Inventory Replenishment	Operational	2	3	4	4	5	5	5	5	5	5	5	5	8 Hours	3 Days	Low-stock alerts and rapid consumption during outbreaks
CBF-2.13	Drug Shortage Monitoring and Mitigation	Operational	2	3	4	4	5	5	5	5	5	5	5	5	8 Hours	3 Days	Global medicine shortages and supplier disruptions
CBF-2.14	Supplier Performance Management	Third-Party Dependency	1	2	2	3	3	4	4	5	5	5	5	5	2 Days	10 Days	Supplier performance deterioration and logistics disruptions
CBF-2.15	Pharmaceutical Recall Coordination	Regulatory	4	5	5	5	5	5	5	5	5	5	5	5	2 Hours	12 Hours	Product safety alerts, contamination incidents, regulator-directed recalls
CBF-2.16	Procurement Risk Monitoring	Operational	1	2	2	3	4	4	5	5	5	5	5	5	1 Day	7 Days	Emerging geopolitical events, transport disruptions, pandemic escalation
CBF-2.17	Pharmaceutical Procurement Information Management	Information	1	2	2	3	3	4	4	5	5	5	5	5	2 Days	10 Days	Regulatory audits, procurement investigations, contract reviews
CBF-2.18	Pharmaceutical Procurement Reporting and Governance	Reputation	1	1	2	2	3	4	4	4	5	5	5	5	3 Days	14 Days	Executive reporting cycles, Ministry reporting deadlines, major incident management

The Impact Over Time assessment enables ALPS Healthcare to understand how disruptions to individual Sub-Critical Business Functions progressively affect the delivery of Pharmaceutical Procurement and Supply Management.

Rather than viewing all interruptions as equally critical, this analysis demonstrates that some functions—such as Pharmaceutical Recall Coordination, Cold Chain and Controlled Storage Coordination, Purchase Order Processing, and Regulatory and Product Compliance Verification—rapidly reach unacceptable impact levels because of their direct influence on patient safety, medicine availability, and regulatory compliance.

Other activities, including supplier evaluation, reporting, and contract management, generally tolerate slightly longer interruptions before significant consequences arise.

These findings establish clear recovery priorities and provide the analytical basis for defining Recovery Time Objectives (RTOs) and Maximum Tolerable Periods of Disruption (MTPDs).

Business functions with short RTOs require resilient technology, predefined manual procedures, trained personnel, and alternate suppliers to minimise downtime.

Functions with longer recovery windows may be restored in later recovery phases while resources remain focused on sustaining critical pharmaceutical supply operations.

The identification of Vulnerable Periods further strengthens Business Continuity Planning by highlighting operational windows when disruption would have the greatest impact, such as disease outbreaks, national vaccination programmes, medicine shortages, supplier contract renewals, emergency imports, and regulatory product recalls.

By integrating impact-over-time analysis with continuity strategies, resource prioritisation, recovery procedures, and contingency planning, ALPS Healthcare enhances its operational resilience and its ability to maintain a safe, compliant, and uninterrupted pharmaceutical supply chain during disruptive events.

eBook 3: Starting Your BCM Implementation
MBCO [x]	P&S [x]	RAR T1 [x]	RAR T2 [x]	RAR T3 [x]	BCS T1 [x]	CBF

CBF-2 Pharmaceutical Procurement and Supply Management
DP	BIAQ P1	BIAQ P2	BIAQ P3	BIAQ P4	BIAQ P5	BIAQ P6

		BCS T2	BCS T3	PD

More Information About Business Continuity Management Courses

To learn more about the course and schedule, click the buttons below for the BCM-300 Business Continuity Management Implementer [BCM-3] and the BCM-5000 Business Continuity Management Expert Implementer [BCM-5].



	Please feel free to send us a note if you have any questions.

View full post